B-Type Natriuretic Peptide: Biomarker of Persistent Pulmonary Hypertension of the Newborn?

Nishant Shah, Girija Natarajan, Sanjeev Aggarwal

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective We assessed the utility of plasma B-type natriuretic peptide (BNP) in infants with persistent pulmonary hypertension of the newborn (PPHN) in the prediction of inhaled nitric oxide (iNO) requirement. Methods This prospective study involved neonates (gestational age ≥ 34 weeks) with PPHN and confirmatory echocardiographic findings. Plasma BNP was assayed once within 12 hours of meeting criteria for iNO requirements and twice every 24 to 48 hours thereafter. Results Infants requiring iNO (n = 14) had higher first BNP levels compared with others (n = 5) (455.5 ± 350.6 vs. 30.1 ± 25.3 ng/dL, p < 0.003). The sensitivity, specificity, positive and negative predictive values, and 95% confidence intervals (CI) for plasma BNP greater than 30 ng/dL to predict iNO requirement were 100 (85-100), 80 (37-80), 94 (80-94), and 100 (46-100)%, respectively. Corresponding values at a cut-off plasma BNP concentration greater than 85 ng/dL were 79 (62-79), 100 (53-100), 100 (79-100), and 63 (33-63)%, respectively. Conclusion BNP had excellent sensitivity and negative predictive value for iNO requirement and above 30 ng/dl maybe a useful prognostic biomarker in PPHN.

Original languageEnglish (US)
Pages (from-to)1045-1049
Number of pages5
JournalAmerican Journal of Perinatology
Volume32
Issue number11
DOIs
StatePublished - May 8 2015

Fingerprint

Persistent Fetal Circulation Syndrome
Brain Natriuretic Peptide
Biomarkers
Nitric Oxide
Gestational Age
Newborn Infant
Prospective Studies
Confidence Intervals
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Shah, Nishant ; Natarajan, Girija ; Aggarwal, Sanjeev. / B-Type Natriuretic Peptide : Biomarker of Persistent Pulmonary Hypertension of the Newborn?. In: American Journal of Perinatology. 2015 ; Vol. 32, No. 11. pp. 1045-1049.
@article{bc0110310584443d8ef61600cdb5ca18,
title = "B-Type Natriuretic Peptide: Biomarker of Persistent Pulmonary Hypertension of the Newborn?",
abstract = "Objective We assessed the utility of plasma B-type natriuretic peptide (BNP) in infants with persistent pulmonary hypertension of the newborn (PPHN) in the prediction of inhaled nitric oxide (iNO) requirement. Methods This prospective study involved neonates (gestational age ≥ 34 weeks) with PPHN and confirmatory echocardiographic findings. Plasma BNP was assayed once within 12 hours of meeting criteria for iNO requirements and twice every 24 to 48 hours thereafter. Results Infants requiring iNO (n = 14) had higher first BNP levels compared with others (n = 5) (455.5 ± 350.6 vs. 30.1 ± 25.3 ng/dL, p < 0.003). The sensitivity, specificity, positive and negative predictive values, and 95{\%} confidence intervals (CI) for plasma BNP greater than 30 ng/dL to predict iNO requirement were 100 (85-100), 80 (37-80), 94 (80-94), and 100 (46-100){\%}, respectively. Corresponding values at a cut-off plasma BNP concentration greater than 85 ng/dL were 79 (62-79), 100 (53-100), 100 (79-100), and 63 (33-63){\%}, respectively. Conclusion BNP had excellent sensitivity and negative predictive value for iNO requirement and above 30 ng/dl maybe a useful prognostic biomarker in PPHN.",
author = "Nishant Shah and Girija Natarajan and Sanjeev Aggarwal",
year = "2015",
month = "5",
day = "8",
doi = "10.1055/s-0035-1548540",
language = "English (US)",
volume = "32",
pages = "1045--1049",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "11",

}

B-Type Natriuretic Peptide : Biomarker of Persistent Pulmonary Hypertension of the Newborn? / Shah, Nishant; Natarajan, Girija; Aggarwal, Sanjeev.

In: American Journal of Perinatology, Vol. 32, No. 11, 08.05.2015, p. 1045-1049.

Research output: Contribution to journalArticle

TY - JOUR

T1 - B-Type Natriuretic Peptide

T2 - Biomarker of Persistent Pulmonary Hypertension of the Newborn?

AU - Shah, Nishant

AU - Natarajan, Girija

AU - Aggarwal, Sanjeev

PY - 2015/5/8

Y1 - 2015/5/8

N2 - Objective We assessed the utility of plasma B-type natriuretic peptide (BNP) in infants with persistent pulmonary hypertension of the newborn (PPHN) in the prediction of inhaled nitric oxide (iNO) requirement. Methods This prospective study involved neonates (gestational age ≥ 34 weeks) with PPHN and confirmatory echocardiographic findings. Plasma BNP was assayed once within 12 hours of meeting criteria for iNO requirements and twice every 24 to 48 hours thereafter. Results Infants requiring iNO (n = 14) had higher first BNP levels compared with others (n = 5) (455.5 ± 350.6 vs. 30.1 ± 25.3 ng/dL, p < 0.003). The sensitivity, specificity, positive and negative predictive values, and 95% confidence intervals (CI) for plasma BNP greater than 30 ng/dL to predict iNO requirement were 100 (85-100), 80 (37-80), 94 (80-94), and 100 (46-100)%, respectively. Corresponding values at a cut-off plasma BNP concentration greater than 85 ng/dL were 79 (62-79), 100 (53-100), 100 (79-100), and 63 (33-63)%, respectively. Conclusion BNP had excellent sensitivity and negative predictive value for iNO requirement and above 30 ng/dl maybe a useful prognostic biomarker in PPHN.

AB - Objective We assessed the utility of plasma B-type natriuretic peptide (BNP) in infants with persistent pulmonary hypertension of the newborn (PPHN) in the prediction of inhaled nitric oxide (iNO) requirement. Methods This prospective study involved neonates (gestational age ≥ 34 weeks) with PPHN and confirmatory echocardiographic findings. Plasma BNP was assayed once within 12 hours of meeting criteria for iNO requirements and twice every 24 to 48 hours thereafter. Results Infants requiring iNO (n = 14) had higher first BNP levels compared with others (n = 5) (455.5 ± 350.6 vs. 30.1 ± 25.3 ng/dL, p < 0.003). The sensitivity, specificity, positive and negative predictive values, and 95% confidence intervals (CI) for plasma BNP greater than 30 ng/dL to predict iNO requirement were 100 (85-100), 80 (37-80), 94 (80-94), and 100 (46-100)%, respectively. Corresponding values at a cut-off plasma BNP concentration greater than 85 ng/dL were 79 (62-79), 100 (53-100), 100 (79-100), and 63 (33-63)%, respectively. Conclusion BNP had excellent sensitivity and negative predictive value for iNO requirement and above 30 ng/dl maybe a useful prognostic biomarker in PPHN.

UR - http://www.scopus.com/inward/record.url?scp=84941558046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941558046&partnerID=8YFLogxK

U2 - 10.1055/s-0035-1548540

DO - 10.1055/s-0035-1548540

M3 - Article

C2 - 26368790

AN - SCOPUS:84941558046

VL - 32

SP - 1045

EP - 1049

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 11

ER -